Disc Medicine announced preliminary third quarter 2026 cash results and the pricing of an upsized public offering of common stock. The company intends to use the capital, which significantly extends its operational runway, to fund clinical development and pre-commercialization activities for its hematology portfolio.
Key Highlights
- Unaudited preliminary cash, cash equivalents, and marketable securities were approximately $682.8 million as of September 30, 2026.
- The upsized public offering of 6,000,000 shares priced at $75.00 per share is expected to generate net proceeds of approximately $422.4 million.
- Management expects its total capital position to fund current operating and capital expenditure plans into 2030.
- An additional 30-day option for 900,000 shares granted to underwriters could increase total net proceeds to approximately $485.9 million.